media

Press Releases

2020
Indian Pharmaceutical Major Hetero Announces The Launch Of Generic RemdesIvir in South Africa for Covid-19 Treatment.
Hetero announces the launch of ‘Favivir’ (Favipiravir) in India to treat mild to moderate Covid-19 patients.
Hetero group company, 'Hetero Healthcare Limited' is all set to supply 20,000 vials of Covifor across the country.
Hetero announces the approval and launch of first generic ‘COVIFOR’ (Remdesivir) in India for the treatment of Covid-19.
Hetero enters into a licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of ‘Remdesivir’ in 127 countries, including India for COVID-19.
Hetero joins the ongoing fight against COVID-19 pandemic by donating INR 10 crores to the Government of Telangana’s relief measures.







2019
Hetero launches TAFFIC, the first generic Bictegravir combination therapy in India.
Hetero launches generic Lapatinib under the brand name ‘Hertab’ in India
Hetero Labs Limited acquires Tarbis Farma, in Spain




2018
Hetero launches ‘TAFERO-EM’ - the first generic fixed-dose combination of ‘Emtricitabine and Tenofovir Alafenamide’ in India
Hetero launches the biosimilar ‘Adalimumab’ under the brand name ‘Mabura’ in India



2017
Hetero receives approval to launch the first-ever generic fixed-dose combination of ‘Darunavir + Ritonavir’ from DCGI.
Hetero receives generic ‘Sofosbuvir+Velpatasvir’ approval for India.
2016
Hetero launches the Biosimilar drug ‘Bevacizumab’ for the treatment of Metastatic Colorectal Cancer (mCRC) under the brand name ‘CizumabTM’
2015
Hetero announces the approval from DCGI for the generic version of ‘Daclatasvir’
Hetero receives the first approval from Drug Controller General of India (DCGI) for fixed-dose combination therapy ‘Ledipasvir-Sofosbuvir’
Hetero announces the launch of Biosimilar Rituximab (MABALLTM) in India
Hetero launches Sofovir
2014
Hetero Drugs bags marketing rights for hepatitis C drug from Gilead